Cancer Rop Co. Ltd. (180400) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cancer Rop Co. Ltd. (180400) has a cash flow conversion efficiency ratio of -0.111x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-10.04 Billion ≈ $-6.81 Million USD) by net assets (₩90.79 Billion ≈ $61.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 180400 stock market capitalisation for the company's overall valuation and market capitalisation.
Cancer Rop Co. Ltd. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Cancer Rop Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cancer Rop Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cancer Rop Co. Ltd. ranked by their cash flow conversion efficiency. Explore 180400 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Multi Spunindo Jaya Tbk.
JK:MSJA
|
0.042x |
|
Thong Guan Industries Bhd
KLSE:7034
|
0.049x |
|
UniTest Incorporation
KQ:086390
|
-0.085x |
|
Zumtobel Group AG
VI:ZAG
|
0.079x |
|
Nnit AS
CO:NNIT
|
0.064x |
|
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
|
0.070x |
|
AGV Products Corp
TW:1217
|
0.017x |
|
Airtel Africa Plc
LSE:AAF
|
0.286x |
Annual Cash Flow Conversion Efficiency for Cancer Rop Co. Ltd. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Cancer Rop Co. Ltd. from 2014 to 2025. View Cancer Rop Co. Ltd. (180400) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩95.76 Billion ≈ $64.90 Million |
₩-18.85 Billion ≈ $-12.78 Million |
-0.197x | +83.92% |
| 2024-12-31 | ₩16.35 Billion ≈ $11.08 Million |
₩-20.03 Billion ≈ $-13.57 Million |
-1.224x | -192.35% |
| 2023-12-31 | ₩28.80 Billion ≈ $19.51 Million |
₩-12.06 Billion ≈ $-8.17 Million |
-0.419x | -1762.27% |
| 2022-12-31 | ₩34.35 Billion ≈ $23.28 Million |
₩865.55 Million ≈ $586.57K |
0.025x | +117.79% |
| 2018-12-31 | ₩34.91 Billion ≈ $23.65 Million |
₩-4.94 Billion ≈ $-3.35 Million |
-0.142x | -130.41% |
| 2017-12-31 | ₩34.75 Billion ≈ $23.55 Million |
₩-2.14 Billion ≈ $-1.45 Million |
-0.061x | -18.79% |
| 2016-12-31 | ₩29.05 Billion ≈ $19.69 Million |
₩-1.50 Billion ≈ $-1.02 Million |
-0.052x | -32.60% |
| 2015-12-31 | ₩21.56 Billion ≈ $14.61 Million |
₩-841.17 Million ≈ $-570.05K |
-0.039x | -135.75% |
| 2014-12-31 | ₩7.18 Billion ≈ $4.87 Million |
₩783.83 Million ≈ $531.19K |
0.109x | -- |
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more